Trevi Therapeutics to Present at Upcoming August Conferences

Rhea-AI Summary

Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced its participation in two key conferences in August 2022. On August 16, CEO Jennifer Good will engage in a fireside chat at the Stifel Biotech Executive Summer Summit. On August 29, CMO Thomas Sciascia and Professor Toby Maher will co-host a workshop at the 6th Annual IPF Summit in Boston, emphasizing chronic cough treatment strategies. Trevi's investigational therapy Haduvio is being developed for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, with FDA Fast Track designation for itch treatment.

NEW HAVEN, Conn., Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio^™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences:

Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences

Stifel Biotech Executive Summer Summit (In-person)
Date: Tuesday, August 16, 2022
Fireside chat presentation: Jennifer Good, President and CEO
Time: 9:00 AM ET

The fireside chat is an invitation-only event and will be available to attending participants.

6^th Annual IPF Summit (In-person)
Date: Monday, August 29, 2022
Time: 11:00 AM ET
Participation: Thomas Sciascia, M.D., Chief Medical Officer, Trevi Therapeutics and Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will host a pre-conference workshop titled "Approaching Chronic Cough with a Fresh Mindset to Bring New Therapeutics to Light."
Location:  Westin Boston Seaport District, Boston MA

For more information about the IPF Summit or to register please visit: https://ipf-summit.com/

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio

Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER has been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com 

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-upcoming-august-conferences-301601734.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What upcoming conferences will Trevi Therapeutics participate in August 2022?

Trevi Therapeutics will present at the Stifel Biotech Executive Summer Summit on August 16 and the 6th Annual IPF Summit on August 29, 2022.

Who will speak at the Stifel Biotech Executive Summer Summit for Trevi Therapeutics?

CEO Jennifer Good will present during the fireside chat at the Stifel Biotech Executive Summer Summit.

What is the focus of the workshop at the 6th Annual IPF Summit?

The workshop, hosted by Dr. Thomas Sciascia and Dr. Toby Maher, is titled 'Approaching Chronic Cough with a Fresh Mindset to Bring New Therapeutics to Light.'

What therapy is Trevi Therapeutics developing?

Trevi Therapeutics is developing Haduvio, an investigational therapy for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis.

What is Haduvio and its significance?

Haduvio is an oral extended-release formulation of nalbuphine, targeting conditions related to itch and cough through opioid receptors.

Has Haduvio received any regulatory designations?

Yes, Haduvio has been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis.